By Fineline Cube 
According to Biogen Inc.’s (NASDAQ: BIIB) Q1 2025 report released this week, the US firm generated USD 2.431 billion in global sales during the quarter, marking an 8% year-on-year (YOY) increase in operational terms. Product revenue was USD 1.727 billion, up 3% YOY.
Revenue Breakdown by Treatment Area
Revenue from multiple sclerosis (MS) products decreased by 10% YOY to USD 953 million, while biosimilars revenue dropped by 5% YOY to USD 181 million. However, newly launched products targeting rare diseases, Alzheimer’s disease (AD), and postpartum depression delivered doubled sales, significantly altering Biogen’s commercial layout.
Rare Disease and Alzheimer’s Disease Business
During the reporting period, the overall revenue of Biogen’s rare disease business was USD 563 million, up 36% YOY, driven by spinal muscular atrophy (SMA) therapy Spinraza (nusinersen) with USD 424 million in sales. The AD drug Leqembi (lecanemab) generated USD 96 million in global sales, with USD 52 million from the US market. Leqembi is expected to ramp up its uptake following recent marketing approval in the European Union (EU).
CEO Commentary and Company Strategy
“Biogen delivered strong first-quarter results, supporting our strategy for long-term growth. We are encouraged by the transformation in our commercial product portfolio, with approximately 45% of total product revenue in the first quarter derived from important medicines outside of our MS business,” said Christopher A. Viehbacher, President and Chief Executive Officer. “In an environment of potential tariffs and medical supply security concerns, Biogen operates a significant manufacturing presence in the US. Roughly 75% of our 2024 US product revenues were generated by products which have manufacturing operations in the US. In addition, Biogen pays substantial taxes in the US since our US market revenues are almost entirely taxable in the US at Federal and state tax rates.”-Fineline Info & Tech